Overall verdict
Buy
6.7/10
1-year performance
-18.73%
Score breakdown
Down 18.7% over 1 year, 40% of the 52-week range.
Strongest: Financial strength 10.0/10. Weakest: Growth 3.6/10.
19 analysts, target +0.1% vs the price.
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring ;
NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry ; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings ; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance ;
and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion ; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes ;
MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors ; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Sector
Health Care
Industry
Health Care Equipment and Supplies
Primary listing
Nyse
United States
CEO
Michael Farrell
Founded
1989
Employees
11 370
Revenue / employee
497 225 USD
Next earnings
October 29, 2026 (estimated)
Institutional holders
- BlackRock, Inc.8.55%
- VANGUARD CAPITAL MANAGEMENT LLC6.57%
- VANGUARD PORTFOLIO MANAGEMENT LLC5.49%
- STATE STREET CORP4.64%
- GEODE CAPITAL MANAGEMENT, LLC3.02%
- Bank of New York Mellon Corp2.91%
- FIRST TRUST ADVISORS LP1.58%
- Invesco Ltd.1.43%
- MORGAN STANLEY1.34%
- Other institutions33.60%
- Rest of the register30.86%
883 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
284.87 USD
52-week low
180.26 USD
1-year performance
-18.73%
Declining
Year-to-date performance
-8.05%
Declining
Drawdown
-21.88%
Marked drawdown
Position in the 52-week range
40% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned more, but shaking 2.1 times harder: for the risk taken, the ETF paid better.
10,000 € placed at the end of September 2009 are worth today
| ResMed | 162 027 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 2.1 times as much as the world ETF.
- Worst fall:-49 % between September 2021 and October 2023. 10,000 € placed at the top fell to 5 133 €. The world ETF, at worst: -34 %. Back to its high in 15 months.
ResMed earned 2 times as much as the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- ResMed: 162 027 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 239.24 USD - 240.47 USD (3 methods agree)
The price implies growth of 4.63% per year; the company grows at 25.00%.
Gross margin 60.3%, net margin 26.9%, ROIC 21.9%, ROE 24.3%.
Net margin
26.94%
Exceptional
Sector 8.18%|S&P 12.97%
Gross margin
60.25%
Fair
Return on equity (ROE)
24.27%
Exceptional
Sector 6.97%|S&P 16.52%
Return on invested capital (ROIC)
21.92%
Exceptional
Free cash flow margin (FCF)
29.18%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.08x
High
Margin stability
4.6 pts
Steady
Revenue to net income
Growth
3.6/10Revenue up 8.6% over 1 year, 12.1% a year over 5, EPS 26.3% a year over 5.
Revenue (trailing 12 months)
5.7Md USD
Revenue growth (1y)
8.58%
Solid
Revenue growth (3y)
33.87%
Solid
EPS growth (1y)
2.42%
Moderate
EPS CAGR (5y)
26.34%
Exceptional
EPS revisions (3 months)
-0.24%
Revised down
Valuation
7.3/10P/E 21.3x, forward P/E 19.0x, EV/EBITDA 14.8x, PEG 0.81. The multiple sits in the 7th percentile of its own 5-year history.
P/E (TTM)
21.3x
Fair
Sector 29.3x|S&P 23.0x
Forward P/E
19.0x
Fair
EV / EBITDA
14.8x
Fair
Sector 16.0x|S&P 14.5x
PEG
0.81
Growth unpriced
Sector 1.76|S&P 0.86
Fair value (reverse DCF)
239.85 USD
Fairly priced
P/E vs its own 5-year history
among the 7% lowest valuations
Far cheaper than usual
Market cap
32.1Md USD
Financial strength
10.0/10Cash covers 178.3% of the debt, net debt/EBITDA -0.3x.
Net debt / EBITDA
-0.3x
Very solid
Gearing (net debt / equity)
-9.82%
Net cash
Cash
1.5Md USD
Cash / market cap
4.59%
Tight
Cash / total debt
178.30%
Net cash
Interest coverage
84.2x
Very solid
Net debt
-647M USD
Equity
6.6Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 221.89 USD
- MM20226.93
- MM50220.32
- MM200226.59
- RSI 1446.2
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-1.06%
200-day average slope, 3 months
-5.95%
50-day average slope, 1 month
+5.63%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.47 % per day
Volatility change
-23.78%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2027 | 11.68 (13) | 12.09 (20) | 5 806 (17) | 2 250 (20) | 1 643 (17) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 24, 2026.
Same sub-industry: 190 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MDT | 7.0 | 7.1 | 114Md USD | 22.0x | 13.9 % | 13.7 % | 7.0 % | 2.0x | 5.4 % | -6.7 % | ||
| 2 | BSX | 6.9 | 7.1 | 64.7Md USD | 18.1x | 17.5 % | 7.5 % | 10.5 % | 1.8x | 5.6 % | -54.3 % | ||
| 3 | SYK | 6.9 | 7.5 | 105Md USD | 28.3x | 14.4 % | 9.4 % | 10.0 % | 1.7x | 4.5 % | -27.6 % | ||
| 4 | RMD | 6.7 | 7.4 | 32.1Md USD | 21.3x | 26.9 % | 8.6 % | 21.9 % | -0.3x | 5.1 % | -18.7 % | ||
| 5 | ABT | 6.6 | 6.3 | 179Md USD | 33.5x | 11.6 % | 13.0 % | 7.5 % | 0.5x | 4.4 % | -25.3 % | ||
| 6 | ISRG | 6.5 | 6.8 | 141Md USD | 45.6x | 28.4 % | 18.5 % | 17.4 % | -1.6x | 2.3 % | -11.4 % | ||
| 7 | SHL | 6.3 | 6.5 | 47.2Md USD | 18.9x | 9.6 % | 1.8 % | 7.4 % | 2.7x | 5.4 % | -20.5 % | ||
| 8 | EW | 6.2 | 5.6 | 50.0Md USD | 51.5x | 15.0 % | 13.6 % | 8.7 % | -2.0x | 2.9 % | 15.4 % | ||
| 9 | BDX | 5.7 | 5.1 | 49.7Md USD | 55.1x | 6.2 % | 5.4 % | 3.2 % | 3.4x | 5.1 % | 22.7 % |
